NEJM editor gives pretrial evidence in Vioxx caseBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7536.255-a (Published 02 February 2006) Cite this as: BMJ 2006;332:255
- Janice Hopkins Tanne
- New York
Trials of three civil actions starting in the United States this month will examine whether Merck's cyclo-oxygenase-2 painkiller Vioxx (rofecoxib) caused the plaintiffs' heart attacks. Lawyers for both plaintiffs and Merck have claimed that editorial information ordered by the court from the New England Journal of Medicine will help their cases on whether Merck promptly and accurately disclosed the drug's cardiac risks.
Gregory Curfman, the executive editor of the New England Journal of Medicine, last week gave a deposition—a sworn pretrial “discovery” testimony—in connection with the forthcoming retrial of a federal case originally tried in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial